VYSCOXA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VYSCOXA (VYSCOXA).
Viscosupplementation agent; hyaluronic acid derivative that replaces synovial fluid, providing lubrication and shock absorption in osteoarthritic joints.
| Metabolism | Not metabolized; cleared by lymphatic system and degraded locally. |
| Excretion | Primarily renal excretion of unchanged drug (60-70%) via glomerular filtration and active tubular secretion; approximately 20% biliary/fecal elimination. |
| Half-life | Terminal elimination half-life of 7-9 hours in patients with normal renal function; prolonged to 20-30 hours in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | 95-98% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.15-0.25 L/kg, indicating limited extravascular distribution; higher Vd in obese patients (up to 0.35 L/kg). |
| Bioavailability | Oral: 70-85% with moderate variability due to first-pass metabolism; intramuscular: approximately 90%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes; Intramuscular: 15-30 minutes. |
| Duration of Action | 10-12 hours after oral administration; up to 24 hours after intravenous dosing due to sustained plasma levels. |
| Molecular Weight | 358.47 |
Intraocular injection: 0.25 mg (0.1 mL of 2.5 mg/mL solution) administered at baseline, month 1, and month 2, then every 3 months.
| Dosage form | SUSPENSION |
| Renal impairment | No dose adjustment required for renal impairment; safety and efficacy not established in severe renal impairment (eGFR <30 mL/min/1.73 m²). |
| Liver impairment | No dose adjustment required for hepatic impairment; not studied in Child-Pugh C cirrhosis. |
| Pediatric use | Safety and efficacy in pediatric patients (<18 years) have not been established. |
| Geriatric use | No specific dose adjustment; limited data in patients ≥75 years, consider increased risk of adverse events. |
| 1st trimester | No adequate studies; use only if potential benefit justifies potential risk to fetus. Animal studies have shown fetal harm. |
| 2nd trimester | No adequate studies; use only if clearly needed. Consider risk of intrauterine growth restriction and oligohydramnios. |
| 3rd trimester | Avoid use during third trimester due to risk of oligohydramnios and neonatal renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for VYSCOXA (VYSCOXA).
| Placental transfer | Readily crosses the placenta; found in fetal circulation. |
| Breastfeeding | Excreted in human milk in low concentrations. Consider risk of infant exposure; benefits of breastfeeding vs. risk of maternal therapy should be weighed. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to VYSCOXASevere hepatic impairment (Child-Pugh Class C)
| Precautions | Do not use in patients with known hypersensitivity to hyaluronic acid preparations; avoid injection in infected or inflamed joints; do not use concurrently with disinfectants containing quaternary ammonium salts; may cause transient local reactions (pain, swelling, effusion). |
| Food/Dietary | No known food interactions. No dietary restrictions. |
| Clinical Pearls | VYSCOXA (hyaluronic acid 1% ophthalmic solution) is used intraocularly during cataract surgery to maintain anterior chamber depth and protect corneal endothelium. Avoid overfilling the chamber; excess can cause post-op intraocular pressure spikes. Use a 27-gauge cannula for injection. Do not reuse single-use vials. Monitor for signs of retained viscoelastic. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | Vyscoxa (vortioxetine) is classified as Pregnancy Category C. First trimester: Limited data; animal studies show adverse effects at high doses but no structural malformations in humans. Second trimester: Risk of serotonin syndrome in neonate if used near term. Third trimester: Potential for persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome (irritability, feeding difficulties). |
| Fetal Monitoring | Monitor for maternal serotonin syndrome (agitation, hyperthermia, clonus) and fetal growth via ultrasound. Assess neonatal adaptation (respiratory distress, feeding problems) at delivery. For lactation, observe infant for sedation, poor feeding, and irritability. |
| Fertility Effects | Animal studies show reduced fertility at high doses. Human data: Possible reversible decrease in libido and ejaculatory dysfunction; no conclusive effect on conception rates. |
| Patient Advice | This medication is used during eye surgery to protect your eye structures. · You may experience temporary blurred vision or mild discomfort after surgery. · Notify your surgeon if you have severe pain, redness, or vision loss. · Follow post-operative instructions carefully, including use of prescribed eye drops. · Avoid rubbing or pressing on your eye after surgery. |